WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011016567) HUMANIZED ANTI-AMYLOID-Β OLIGOMER ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/016567    International Application No.:    PCT/JP2010/063430
Publication Date: 10.02.2011 International Filing Date: 06.08.2010
IPC:
C12N 15/09 (2006.01), A61K 39/395 (2006.01), A61P 25/28 (2006.01), C07K 16/18 (2006.01), C07K 16/46 (2006.01)
Applicants: Kyowa Hakko Kirin Co., Ltd. [JP/JP]; 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 1008185 (JP) (For All Designated States Except US).
KUBOTA Tsuguo; (For US Only).
SUZUKI Nobuyuki; (For US Only)
Inventors: KUBOTA Tsuguo; .
SUZUKI Nobuyuki;
Agent: OGURI Shohei; Eikoh Patent Firm, Toranomon East Bldg. 10F, 7-13, Nishi-Shimbashi 1-chome, Minato-ku, Tokyo 1050003 (JP)
Priority Data:
61/232038 07.08.2009 US
Title (EN) HUMANIZED ANTI-AMYLOID-Β OLIGOMER ANTIBODY
(FR) ANTICORPS OLIGOMÈRE HUMANISÉ ANTI-SUBSTANCE Β-AMYLOÏDE
(JA) 抗アミロイドβオリゴマーヒト化抗体
Abstract: front page image
(EN)A humanized antibody which cannot bind to an Aβ monomer but can bind only to an Aβ oligomer specifically; an anti-cognitive impairment agent, a therapeutic agent for Alzheimer's disease, a senile plaque formation inhibitor or an Aβ-amyloid fibril formation inhibitor, each of which comprises the antibody as an active ingredient; a method for preventing and/or treating cognitive impairment or Alzheimer's disease, which comprises a step of administering the antibody; and a method for preventing the progression of Alzheimer's disease, which comprises a step of administering the antibody.
(FR)La présente invention concerne un anticorps humanisé ne pouvant pas se lier à un monomère Aβ, mais pouvant, uniquement et de façon spécifique, se lier à un oligomère Aβ ; un agent anti-déficience cognitive, un agent thérapeutique pour la maladie d'Alzheimer, un inhibiteur de la formation des plaques séniles ou un inhibiteur de la formation des fibrilles de substance β-amyloïde, chacun contenant ledit anticorps en tant que principe actif ; une méthode de prévention et/ou de traitement de la déficience cognitive ou de la maladie d'Alzheimer, comprenant une étape consistant à administrer ledit anticorps ; et une méthode permettant de prévenir la progression de la maladie d'Alzheimer et comprenant, également, une étape consistant à administrer ledit anticorps.
(JA) Aβモノマーに結合せず、Aβオリゴマーのみに特異的に結合するヒト化抗体、該抗体を有効成分として含有する、抗認知機能障害剤、アルツハイマー病治療剤、老人斑形成抑制剤またはAβアミロイド線維形成阻害剤、該抗体を投与する工程を含む、認知機能障害またはアルツハイマー病の予防および治療の少なくとも一方のための方法、並びに該抗体を投与する工程を含む、アルツハイマー病の進行を抑制する方法。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)